Trial Profile
A Subject-, Investigator-, and Sponsor-blinded, Randomized, Placebo-controlled, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Feb 2024
Price :
$35
*
At a glance
- Drugs Ianalumab (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 13 Feb 2023 Status changed from completed to discontinued.
- 06 Sep 2022 Status changed from discontinued to completed.
- 08 Mar 2022 Status changed from completed to discontinued.